MEI Pharma Future Growth

Future criteria checks 0/6

MEI Pharma's revenue and earnings are forecast to decline at 21.1% and 4% per annum respectively while EPS is expected to grow by 16.3% per annum.

Key information

-4.0%

Earnings growth rate

16.3%

EPS growth rate

Biotechs earnings growth31.3%
Revenue growth rate-21.1%
Future return on equityn/a
Analyst coverage

Low

Last updated23 Jun 2023

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:MMI0 - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/202625-47N/AN/A1
6/30/20257-61N/AN/A2
6/30/20241-67N/AN/A2
6/30/202348-38N/AN/A2
3/31/202359-38-57-57N/A
12/31/202263-31-62-62N/A
9/30/202242-54-56-56N/A
6/30/202241-54-49-49N/A
3/31/202237-47-45-44N/A
12/31/202135-64-43-43N/A
9/30/202136-60-35-35N/A
6/30/202135-41-33-32N/A
3/31/202152-534848N/A
12/31/202045-315254N/A
9/30/202033-434243N/A
6/30/202028-473334N/A
3/31/20205-24-44-43N/A
12/31/20195-38-44-44N/A
9/30/20196-5-31-31N/A
6/30/20195-17-30-29N/A
3/31/20194-39-25-25N/A
12/31/20184-28-20-20N/A
9/30/20182-46-27-27N/A
6/30/20182-40-21-21N/A
3/31/20182-25-21-21N/A
12/31/20176-20-13-13N/A
9/30/201722-2-12-12N/A
6/30/201723333N/A
3/31/201723133N/A
12/31/201618-4N/A-3N/A
9/30/20161-21N/A-3N/A
6/30/2016N/A-21N/A-18N/A
3/31/2016N/A-21N/A-21N/A
12/31/2015N/A-24N/A-25N/A
9/30/2015N/A-28N/A-27N/A
6/30/2015N/A-33N/A-28N/A
3/31/2015N/A-36N/A-27N/A
12/31/2014N/A-34N/A-24N/A
9/30/2014N/A-31N/A-22N/A
6/30/2014N/A-27N/A-19N/A
3/31/2014N/A-22N/A-16N/A
12/31/2013N/A-17N/A-14N/A
9/30/2013N/A-14N/A-12N/A
6/30/2013N/A-11N/A-10N/A
3/31/2013N/A-10N/A-9N/A
12/31/2012N/A-10N/A-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MMI0 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MMI0 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MMI0 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MMI0's revenue is expected to decline over the next 3 years (-21.1% per year).

High Growth Revenue: MMI0's revenue is forecast to decline over the next 3 years (-21.1% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MMI0's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.